Home / Peptide guides / NSW peptide ER surge
Peptide ER visits exploded in NSW: 5 a month to 217
Australia's biggest state just put hard numbers on the gray-market peptide boom, and retatrutide is all over them.
New NSW Health surveillance data counts 1,180 emergency department presentations that mentioned unapproved peptide use between 1 July 2025 and 30 September 2026. Monthly visits went from 5 in July 2025 to 217 in September 2026 (NSW Health report; NSW Government release).
The numbers, plainly
| Measure | Figure |
|---|---|
| Total ED presentations (age 16+) | 1,180 |
| Monthly, July 2025 → September 2026 | 5 → 217 |
| Mentioned retatrutide | 833 (71%) |
| Mentioned "peptide" or another unapproved peptide (BPC-157, TB-500, CJC-1295, GHK-Cu, ipamorelin, melanotan) | 445 (38%) |
| Mentioned both | 98 (8%) |
| Admitted to hospital from the ED | 18% |
| Biggest age groups | 25–34: 32%; 35–44: 26%; 16–24: 25% |
| Men / women | 51% / 49% |
All figures from the NSW Health surveillance report (Centre for Epidemiology and Evidence, October 2026; report page). The groups overlap, so 833 + 445 − 98 = 1,180.
What sent people to the ER
The most common primary diagnoses were gut problems (abdominal pain, nausea, vomiting), heart-related issues including chest pain, and anaphylaxis, allergic reactions and medication reactions (NSW Health). NSW Health says clinicians are also reporting serious illness including kidney damage and liver injury (NSW Government).
NSW Chief Health Officer Dr Kerry Chant: "A professional looking website, a label, purity claim, reviews, or influencer endorsement is not proof of what is inside the product." (NSW Government)
How to read these numbers
- It's visits, not people. A repeat visit counts again.
- It's a mention, not proof of cause. The report says it "cannot conclude that peptide use caused the presentation" (NSW Health).
- It's probably an undercount. Peptide use only counts if it was mentioned at triage and written down; the report says the level of under-capture couldn't be estimated.
- "Retatrutide" means the label, not a lab test. Nobody verified what was in the vials.
What it means if you're in the US
Retatrutide isn't approved in Australia or the US. Lilly plans to submit it to the FDA in Q1 2027 (our tracker). What's sold online as "retatrutide" is a research chemical with no FDA quality checks. Wondering what is approved? See our FDA-approved peptides list.
Not FDA-approved; sold for research only. Known risks: GI effects, chest pain, allergic reactions and reported kidney and liver injury in the NSW data (NSW Health; NSW Government). Choose a tested source.
Also covered by AusDoc, the Newcastle Herald and ABC News.
Get the next big peptide study first
New results like this, explained plainly in five minutes, every Friday. Free.
NSW peptide surge FAQ
How many people went to hospital after using peptides in NSW?
NSW Health counted 1,180 emergency department presentations that mentioned unapproved peptide use between 1 July 2025 and 30 September 2026, in people aged 16 and over (NSW Health report). That counts visits, not unique people, and doesn't prove the peptide caused the visit.
Which peptide showed up most?
Retatrutide. It was mentioned in 833 of the 1,180 presentations (71%) (NSW Health). Retatrutide is an investigational drug that isn't approved in Australia or the US.
Is retatrutide approved anywhere?
No. NSW Health says none of BPC-157, GHK-Cu, TB-500, retatrutide or CJC-1295 is approved in Australia for any purpose (NSW Government). In the US it's still in phase 3; see our retatrutide FDA status tracker.
Not medical advice. Education only. Talk to a licensed clinician about your health.